<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181168</url>
  </required_header>
  <id_info>
    <org_study_id>THYR01105ORP</org_study_id>
    <secondary_id>JHM IRB #1</secondary_id>
    <nct_id>NCT00181168</nct_id>
  </id_info>
  <brief_title>Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer</brief_title>
  <official_title>Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-differentiated Epithelial Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine [for patients with previously treated
      well-differentiated thyroid cancer and evidence of residual disease based on serum
      thyroglobulin (Tg) level] whether positron emission tomography-computed tomography (PET-CT)
      fusion scanning performed after recombinant thyroid-stimulating hormone (TSH) (rTSH,
      thyrotropin alfa for injection) will be more sensitive for the detection of disease sites
      than PET-CT scanning without rTSH. The study will also determine if this information will
      significantly alter the therapeutic approach in some patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PET/CT was performed before (basal PET) and 24 - 48 h after rhTSH administration (rhTSH-PET)
      in 63 patients (52 papillary and 11 follicular thyroid cancers). Images were blindly analyzed
      by two readers. The proposed treatment plan was prospectively assessed before basal PET,
      after basal PET, and again after rhTSH-PET.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET-CT Fusion Scanning Sensitivity</measure>
    <time_frame>21 Days</time_frame>
    <description>PET/CT was performed before (basal PET) and 24-48 h after rhTSH administration (rhTSH-PET) in 63 patients (52 papillary and 11 follicular thyroid cancers). Images were blindly analyzed by two readers. The proposed treatment plan was prospectively assessed before basal PET, after basal PET, and again after rhTSH-PET.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increased Fluorodeoxyglucose (FDG) PET Standardized Uptake Value (SUV) After rTSH Specificity</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Euthyroid Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Euthyroid Group: Subjects received rhTSH to prepare for radioiodine therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypothyroid Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Hypothyroid Group: Thyroid hormone treatment was withheld before radioiodine therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Euthyroid Group</intervention_name>
    <description>Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.</description>
    <arm_group_label>Euthyroid Group</arm_group_label>
    <other_name>Recombinant Human TSH (rhTSH)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (aged ≥ 18 years) with history of treated well-differentiated epithelial
             thyroid carcinoma (papillary, follicular or Hurthle cell), for which total or near
             total thyroidectomy plus postoperative radioiodine remnant ablation with 131-I has
             either been performed or found to be unnecessary by radioiodine imaging after TSH
             stimulation.

          -  Serum thyroglobulin (Tg) concentration ≥ 10 ng/mL (in the absence of interfering Tg
             autoantibodies).

          -  No findings of a &quot;qualifying&quot; radioiodine whole body scan that are sufficient to
             localize the disease suspected on the basis of the serum Tg.

          -  Inconclusive disease localization despite clinical assessment, cervical sonography, CT
             or magnetic resonance (MR) of the chest, and when appropriate other imaging and biopsy
             procedures. Patients must have no more than three foci of known or suspected
             extra-cervical metastasis.

          -  Must be in stable medical condition.

          -  Must be able to fully understand the protocol and be compliant with instructions.

        Exclusion Criteria:

          -  Diabetes mellitus, due to interference with fluorodeoxyglucose (FDG) PET scanning.

          -  Claustrophobia, inability to lay supine, or other factors preventing cooperation with
             scanning procedures.

          -  Withdrawal of thyroid hormone or rTSH administration within the preceding month.

          -  Presence of circulating Tg autoantibodies interfering with serum Tg measurement.

          -  Women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul W Ladenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Division of Endocrinology &amp; Metabolism</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2004 Jan;89(1):91-5.</citation>
    <PMID>14715833</PMID>
  </reference>
  <results_reference>
    <citation>Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006 Mar;91(3):926-32. Epub 2005 Dec 29.</citation>
    <PMID>16384850</PMID>
  </results_reference>
  <results_reference>
    <citation>Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009 Apr;94(4):1310-6. doi: 10.1210/jc.2008-1747. Epub 2009 Jan 21.</citation>
    <PMID>19158200</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>April 21, 2015</results_first_submitted>
  <results_first_submitted_qc>October 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2018</results_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thyroid cancer</keyword>
  <keyword>PET scan</keyword>
  <keyword>recombinant thyrotropin</keyword>
  <keyword>thyroglobulin</keyword>
  <keyword>Thyroid cancer, differentiated epithelial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Euthyroid Group</title>
          <description>Subjects received rhTSH to prepare for radioiodine therapy</description>
        </group>
        <group group_id="P2">
          <title>Hypothyroid Group</title>
          <description>Thyroid hormone treatment was withheld before radioiodine therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Euthyroid Group</title>
          <description>Adults (age &gt;18 years) with a history of treated well-differentiated epithelial thyroid carcinoma (papillary, follicular, or Hürthle cell), for which total or near total thyroidectomy plus postoperative radioiodine remnant ablation with 131-I has either been performed or found to be unnecessary by radioiodine imaging after TSH stimulation.
Subjects received rhTSH to prepare for radioiodine therapy</description>
        </group>
        <group group_id="B2">
          <title>Hypothyroid Group</title>
          <description>Adults (age &gt;18 years) with a history of treated well-differentiated epithelial thyroid carcinoma (papillary, follicular, or Hürthle cell), for which total or near total thyroidectomy plus postoperative radioiodine remnant ablation with 131-I has either been performed or found to be unnecessary by radioiodine imaging after TSH stimulation.
Thyroid hormone treatment was withheld before radioiodine therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PET-CT Fusion Scanning Sensitivity</title>
        <description>PET/CT was performed before (basal PET) and 24-48 h after rhTSH administration (rhTSH-PET) in 63 patients (52 papillary and 11 follicular thyroid cancers). Images were blindly analyzed by two readers. The proposed treatment plan was prospectively assessed before basal PET, after basal PET, and again after rhTSH-PET.</description>
        <time_frame>21 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Euthyroid Group</title>
            <description>Subjects received rhTSH to prepare for radioiodine therapy.</description>
          </group>
          <group group_id="O2">
            <title>Hypothyroid Group</title>
            <description>Thyroid hormone treatment was withheld before radioiodine therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>PET-CT Fusion Scanning Sensitivity</title>
          <description>PET/CT was performed before (basal PET) and 24-48 h after rhTSH administration (rhTSH-PET) in 63 patients (52 papillary and 11 follicular thyroid cancers). Images were blindly analyzed by two readers. The proposed treatment plan was prospectively assessed before basal PET, after basal PET, and again after rhTSH-PET.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="36" upper_limit="62"/>
                    <measurement group_id="O2" value="54" lower_limit="41" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increased Fluorodeoxyglucose (FDG) PET Standardized Uptake Value (SUV) After rTSH Specificity</title>
        <time_frame>21 Days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Euthyroid Group</title>
          <description>Adults (age &gt;18 years) with a history of treated well-differentiated epithelial thyroid carcinoma (papillary, follicular, or Hürthle cell), for which total or near total thyroidectomy plus postoperative radioiodine remnant ablation with 131-I has either been performed or found to be unnecessary by radioiodine imaging after TSH stimulation.
Subjects received rhTSH to prepare for radioiodine therapy</description>
        </group>
        <group group_id="E2">
          <title>Hypothyroid Group</title>
          <description>Adults (age &gt;18 years) with a history of treated well-differentiated epithelial thyroid carcinoma (papillary, follicular, or Hürthle cell), for which total or near total thyroidectomy plus postoperative radioiodine remnant ablation with 131-I has either been performed or found to be unnecessary by radioiodine imaging after TSH stimulation.
Thyroid hormone treatment was withheld before radioiodine therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul W. Ladenson, MD, Professor and PI</name_or_title>
      <organization>Johns Hopkins Univ</organization>
      <phone>4109553663</phone>
      <email>ladenson@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

